EMA Clarifies Reporting Requirement for Off-Label Drug Use

Drug Industry Daily
A A
Drugmakers are expected to collect individual cases of suspected adverse reactions linked to off-label use but not individual reports when there has been no associated adverse event, the EMA said Friday.

To View This Article:

Login

Subscribe To Drug Industry Daily